{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:50:49Z","timestamp":1787964649519,"version":"build-2784847793"},"reference-count":56,"publisher":"BMJ","issue":"11","funder":[{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Helsinki University Hospital","award":["TYH2020302"],"award-info":[{"award-number":["TYH2020302"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2022,5,16]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>The Cancer Genome Atlas research network performed a genome-wide analysis of endometrial carcinomas in 2013 and classified tumours into four distinct subgroups: polymerase-\u03f5 ultramutated, microsatellite unstable hypermutated, copy-number low and copy-number high. These molecular alterations are mostly mutually exclusive as only about 3% of tumours exhibit more than one molecular signature. Apart from the polymerase-\u03f5 ultramutated subgroup, molecular classification can be reproduced by using surrogate markers. This has facilitated the implementation of molecular diagnostics into routine patient care. Molecular subgroups are associated with different prognoses; thus, improved risk assessment is their most obvious clinical application. However, based on their unique molecular architectures, molecular subgroups should not be regarded simply as risk groups but rather as distinct diseases. This has prompted us and others to examine the role of molecular subgroups in modifying the prognostic effect of traditional risk factors, including clinical factors, uterine factors and tissue biomarkers, and in predicting the response to adjuvant therapies. In the following review, we summarise the current knowledge of molecularly classified endometrial carcinoma and present, based on our own experience, a proposal for implementing molecular classification into daily practice in pathology laboratories.<\/jats:p>","DOI":"10.1136\/jclinpath-2022-208345","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T13:20:18Z","timestamp":1653916818000},"page":"731-738","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Molecular classification of endometrial carcinoma: a clinically oriented review"],"prefix":"10.1136","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4372-2367","authenticated-orcid":false,"given":"Mikko","family":"Loukovaara","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annukka","family":"Pasanen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Helsinki University Hospital and Research Program in Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"B\u00fctzow","sequence":"additional","affiliation":[{"name":"Department of Pathology, Helsinki University Hospital and Research Program in Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,5,30]]},"reference":[{"key":"2025121400550500000_75.11.731.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025121400550500000_75.11.731.2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(83)90111-7"},{"key":"2025121400550500000_75.11.731.3","doi-asserted-by":"publisher","DOI":"10.1038\/nature12113"},{"key":"2025121400550500000_75.11.731.4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2020.02.014","article-title":"A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer","volume":"157","author":"Praiss","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2025121400550500000_75.11.731.5","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.190"},{"key":"2025121400550500000_75.11.731.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2878"},{"key":"2025121400550500000_75.11.731.7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30496"},{"key":"2025121400550500000_75.11.731.8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy058"},{"key":"2025121400550500000_75.11.731.9","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ejogrb.2020.10.031","article-title":"Molecular characterization in the prediction of disease extent in endometrial carcinoma","volume":"256","author":"Kolehmainen","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2025121400550500000_75.11.731.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242733","article-title":"Clinical factors as prognostic variables among molecular subgroups of endometrial cancer","volume":"15","author":"Kolehmainen","year":"2020","journal-title":"PLoS One"},{"key":"2025121400550500000_75.11.731.11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"2025121400550500000_75.11.731.12","doi-asserted-by":"publisher","DOI":"10.1002\/path.5372"},{"key":"2025121400550500000_75.11.731.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.10.037"},{"key":"2025121400550500000_75.11.731.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.06.006"},{"key":"2025121400550500000_75.11.731.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.04.013"},{"key":"2025121400550500000_75.11.731.16","doi-asserted-by":"crossref","first-page":"363.e1","DOI":"10.1016\/j.ajog.2013.12.025","article-title":"Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma","volume":"210","author":"Benedetti Panici","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"2025121400550500000_75.11.731.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.10.020"},{"key":"2025121400550500000_75.11.731.18","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31827b8430"},{"key":"2025121400550500000_75.11.731.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.07.095"},{"key":"2025121400550500000_75.11.731.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253472","article-title":"Differential impact of clinicopathological risk factors within the 2 largest promise molecular subgroups of endometrial carcinoma","volume":"16","author":"Pasanen","year":"2021","journal-title":"PLoS One"},{"key":"2025121400550500000_75.11.731.21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt144"},{"key":"2025121400550500000_75.11.731.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.07.014"},{"key":"2025121400550500000_75.11.731.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.02.003"},{"key":"2025121400550500000_75.11.731.24","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000801"},{"key":"2025121400550500000_75.11.731.25","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1Cam further stratifies endometrial carcinoma patients with no specific molecular risk profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br J Cancer"},{"key":"2025121400550500000_75.11.731.26","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181f39849"},{"key":"2025121400550500000_75.11.731.27","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001020"},{"key":"2025121400550500000_75.11.731.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.07.090"},{"key":"2025121400550500000_75.11.731.29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ygyno.2019.06.012","article-title":"Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: towards early personalized patient management","volume":"154","author":"Abdulfatah","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2025121400550500000_75.11.731.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.08.019"},{"key":"2025121400550500000_75.11.731.31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133124","article-title":"Mismatch repair deficiency as a predictive and prognostic biomarker in molecularly classified endometrial carcinoma","volume":"13","author":"Loukovaara","year":"2021","journal-title":"Cancers"},{"key":"2025121400550500000_75.11.731.32","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/cam4.3691","article-title":"Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer","volume":"10","author":"Loukovaara","year":"2021","journal-title":"Cancer Med"},{"key":"2025121400550500000_75.11.731.33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2021.01.002","article-title":"Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study","volume":"161","author":"Kim","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2025121400550500000_75.11.731.34","first-page":"419","article-title":"Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients","volume":"56","author":"Aalders","year":"1980","journal-title":"Obstet Gynecol"},{"key":"2025121400550500000_75.11.731.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02139-5"},{"key":"2025121400550500000_75.11.731.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2003.11.048"},{"key":"2025121400550500000_75.11.731.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61767-5"},{"key":"2025121400550500000_75.11.731.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62163-2"},{"key":"2025121400550500000_75.11.731.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.04.014"},{"key":"2025121400550500000_75.11.731.40","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.19.00362","article-title":"External beam, brachytherapy, or chemotherapy? defining adjuvant therapy for early-stage and high- and High-Intermediate-Risk endometrial cancer","volume":"37","author":"Jang","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025121400550500000_75.11.731.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.06.003"},{"key":"2025121400550500000_75.11.731.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.06.002"},{"key":"2025121400550500000_75.11.731.43","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025121400550500000_75.11.731.44","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01575"},{"key":"2025121400550500000_75.11.731.45","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-002230"},{"key":"2025121400550500000_75.11.731.46","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ygyno.2020.12.021","article-title":"Endometrial cancer: a Society of gynecologic oncology evidence-based review and recommendations","volume":"160","author":"Hamilton","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2025121400550500000_75.11.731.47","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025121400550500000_75.11.731.48","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ygyno.2019.03.097","article-title":"Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer","volume":"154","author":"Reijnen","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2025121400550500000_75.11.731.49","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ajog.2020.10.003","article-title":"Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer","volume":"224","author":"Chung","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"2025121400550500000_75.11.731.50","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"2025121400550500000_75.11.731.51","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the Anti-Programmed death 1 monoclonal antibody Dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025121400550500000_75.11.731.52","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025121400550500000_75.11.731.53","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/PAS.0000000000001395","article-title":"Pd-L1 expression in endometrial carcinoma cells and intratumoral immune cells: differences across histologic and TCGA-based molecular subgroups","volume":"44","author":"Pasanen","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"2025121400550500000_75.11.731.54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1443"},{"key":"2025121400550500000_75.11.731.55","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ygyno.2020.12.010","article-title":"Clinical significance of homologous recombination deficiency score testing in endometrial cancer","volume":"160","author":"Siedel","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2025121400550500000_75.11.731.56","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030651","article-title":"Clinicopathologic vs. molecular integrated prognostication of endometrial carcinoma by European guidelines","volume":"14","author":"Loukovaara","year":"2022","journal-title":"Cancers"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2022-208345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:55:15Z","timestamp":1765702515000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2022-208345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":56,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,10,18]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/jclinpath-2022-208345"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2022-208345","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,30]]}}}